Creative Medical Technology Holdings, Inc. Common Stock (CELZ) is a publicly traded Healthcare sector company. As of May 21, 2026, CELZ trades at $2.26 with a market cap of $8.24M and a P/E ratio of 0.00. CELZ moved +0.00% today. Year to date, CELZ is +11.27%; over the trailing twelve months it is +13.50%. Its 52-week range spans $1.50 to $6.90. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces CELZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Creative Medical Secures Second WHO Proposed INN 'etaroleucel' for CELZ-101: Creative Medical achieved its second WHO International Nonproprietary Name milestone with the proposed INN 'etaroleucel' for autologous Treg therapy CELZ-101, now entering the formal objection period. This builds on the 'olastrocel' naming for allogeneic CELZ-201 and enhances global regulatory positioning for its cell therapy programs.
| Metric | Value |
|---|---|
| Price | $2.26 |
| Market Cap | $8.24M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.90 |
| 52-Week Low | $1.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.00K |
| Net Income | $-6.00M |
| Gross Margin | 63.43% |
1 analysts cover CELZ: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.